Related Experiment Video
Updated: Jul 20, 2026
06:01
A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
Published on: August 18, 2015
Is plasma homocysteine a modifiable risk factor for stroke?
1Stroke Unit, Department of Neurology, Royal Perth Hospital, Perth, WA, Australia. gjhankey@cyllene.uwa.edu.au
Nature Clinical Practice. Neurology
|August 26, 2006
Summary
High homocysteine levels are linked to stroke risk, but B-vitamin therapy did not significantly reduce stroke in a major trial. More research is needed to confirm if lowering homocysteine prevents stroke.
Area of Science:
- Neurology
- Cardiovascular Medicine
- Nutritional Science
Background:
- Elevated plasma total homocysteine (tHcy) is associated with increased risk of atherothrombotic vascular disease, including ischemic stroke.
- This association is independent of other vascular risk factors and is biologically plausible.
- However, randomized controlled trials have not yet confirmed a causal relationship.
Purpose of the Study:
- To investigate whether lowering plasma total homocysteine (tHcy) levels with B-vitamin therapy reduces the risk of stroke.
- To evaluate the efficacy of B-vitamin supplementation in preventing recurrent ischemic stroke.
Main Methods:
- The Vitamins In Stroke Prevention (VISP) trial involved 3,680 patients with recent ischemic stroke.
- Participants received either B-vitamin therapy or a placebo.
- Plasma tHcy levels were monitored, and stroke events were recorded.
Main Results:
- B-vitamin therapy did not result in a statistically significant reduction in the relative risk of stroke.
- The trial could not reliably exclude a modest but potentially important risk reduction of up to 20% in stroke.
- No significant effect on stroke prevention was observed with homocysteine lowering therapy.
Conclusions:
- There is currently insufficient evidence to establish homocysteine as a modifiable causal risk factor for stroke.
- Routine screening for, or treatment of, elevated tHcy concentrations with folic acid and other vitamins is not recommended for stroke prevention based on current data.
Related Concept Videos
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:29Hemorrhagic Stroke ll: Pathophysiology
A hemorrhagic stroke develops when a cerebral blood vessel ruptures, allowing blood to escape into the surrounding brain tissue, as in intracerebral hemorrhage (ICH), or into the subarachnoid space, as in subarachnoid hemorrhage (SAH). Because the skull is a rigid compartment, the sudden presence of extravascular blood rapidly increases intracranial pressure and compresses adjacent neural structures, leading to immediate tissue injury and impaired cerebral perfusion.Mass Effect and Primary...
01:15Ischemic Stroke l: Introduction
Ischemic stroke is an acute cerebrovascular condition in which blood flow to a brain region is suddenly interrupted, leading to tissue infarction. Neurons depend on continuous oxygen and glucose supply, so even brief reductions in perfusion cause energy failure, ionic imbalance, and irreversible injury. Ischemic strokes are classified into thrombotic and embolic types based on their underlying mechanisms.Thrombotic MechanismsThrombotic stroke develops when a clot forms within a cerebral artery.
01:17Hemorrhagic Stroke l: Introduction
A hemorrhagic stroke is an acute neurological event that occurs when a weakened cerebral blood vessel ruptures, allowing blood to accumulate within or around the brain. The sudden release of blood forms a focal hematoma that increases intracranial pressure, displaces neural tissue, and can obstruct cerebrospinal fluid pathways. These effects may be compounded by intraventricular extension of the hemorrhage, cerebral edema, or compression of adjacent structures, all of which contribute to...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...